+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Octapharma AG - logo

Octapharma is a privately-owned global human proteins manufacturer headquartered in Lachen, Switzerland. It develops human proteins that are derived from human plasma and human cell-lines. The company provides biopharmaceutical products and therapies for haematology, intensive care & emergency medicine, and immunotherapy. Octapharma owns and operates six state of the art plants, employing over 6,000 workers globally. It was founded in 1983 by Wolfgang Marguerre.

From
Sepsis- Pipeline Insight, 2024 - Product Thumbnail Image

Sepsis- Pipeline Insight, 2024

  • Clinical Trials
  • August 2024
  • 80 Pages
  • Global
From
From
From
From
From
From
From
Plasma Protein Therapeutics Market Report and Forecast 2024-2032 - Product Thumbnail Image

Plasma Protein Therapeutics Market Report and Forecast 2024-2032

  • Report
  • October 2023
  • 140 Pages
  • Global
From
From
Intravenous Immunoglobulin Global Market Report 2024 - Product Thumbnail Image

Intravenous Immunoglobulin Global Market Report 2024

  • Report
  • February 2024
  • 200 Pages
  • Global
From
Immunoglobulins Global Market Report 2024 - Product Thumbnail Image

Immunoglobulins Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Plasma Fractionation Market Report and Forecast 2023-2031 - Product Thumbnail Image

Plasma Fractionation Market Report and Forecast 2023-2031

  • Report
  • May 2023
  • 147 Pages
  • Global
From
Plasma Derived Therapy Market Report and Forecast 2024-2032 - Product Thumbnail Image

Plasma Derived Therapy Market Report and Forecast 2024-2032

  • Report
  • September 2023
  • 160 Pages
  • Global
From
Complement C1 inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Complement C1 inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Loading Indicator